BridgeBio Pharma, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BridgeBio Pharma, Inc. on August 17, 2026, regarding events occurring on August 13, 2026. The filing details the entry into a material definitive agreement for a secondary offering of common stock by a selling stockholder.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial data points relate to the capital transaction:
- Shares Offered: 5,000,000 shares of common stock.
- Offering Price: $78.00 per share.
- Proceeds to Company: $0. The Company will not receive any proceeds from this sale.
- Selling Stockholder: KKR Genetic Disorder L.P.
Material Changes
The material change reported is the execution of an Underwriting Agreement for a secondary offering. This transaction increases the number of shares outstanding in the public market but does not alter the Company's cash position or capital structure directly, as the proceeds are received by the selling stockholder.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, operational outlook, or specific risk factors beyond standard legal disclosures. The Company agreed to customary representations, warranties, and indemnification obligations to the underwriters (William Blair & Company, L.L.C., Goldman Sachs & Co. LLC, and KKR Capital Markets LLC) regarding liabilities under the Securities Act of 1933. The sale was expected to be completed on August 17, 2026.
Investor Verification Checklist
- Verify the total number of shares outstanding post-offering to assess potential dilution impact.
- Confirm the identity and remaining holdings of the Selling Stockholder (KKR Genetic Disorder L.P.).
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific lock-up provisions or covenants.
- Check subsequent filings for the final closing confirmation and any changes to the offering price.